Every 10-Q that Rigel Pharmaceuticals Inc. (New) (RIGL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RIGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RIGL filings page.
Rigel Pharmaceuticals, Inc. reported total revenues of 78,703 (in thousands) for the quarter ended June 30, 2026, generating net income of 17,290 (in thousands), or $0.88 diluted earnings per share. For the first six months of 2026, revenues were 137,521 (in thousands) and net income was 25,944 (in thousands). Product sales grew, while contract revenues declined versus 2025, which had included a 39,981 (in thousands) release of a Lilly cost share liability.
Cash, cash equivalents, restricted cash and short-term investments totaled 95,386 (in thousands) at June 30, 2026, with stockholders’ equity of 425,422 (in thousands). The company repaid a prior term loan and entered a new revolving credit facility, with $40.0 million outstanding at quarter end. TAVALISSE net product sales were $84.7 million for the six months ended June 30, 2026, up 24% from $68.5 million, REZLIDHIA sales were $17.0 million, and GAVRETO sales were $20.3 million. Rigel licensed VEPPANU from Arvinas and Pfizer, paying a $70.0 million upfront fee and gaining rights to a fourth FDA-approved product expected to launch in mid-August 2026, while its prior global collaboration with Lilly for ocadusertib was terminated, with rights reverting to Rigel.
Rigel Pharmaceuticals reported a profitable first quarter of 2026 with higher product sales and continued investment in its pipeline. Total revenues were $58.8 million, up from $53.3 million a year earlier, driven by net product sales of $54.9 million. TAVALISSE, REZLIDHIA and GAVRETO net sales were $37.3 million, $8.0 million and $9.6 million, respectively, each growing versus 2025.
Net income was $8.7 million compared with $11.4 million, as operating expenses and a higher $3.0 million tax provision offset revenue gains. Diluted EPS was $0.44. Cash, cash equivalents and short‑term investments totaled $146.7 million, with $45.0 million of term debt outstanding at March 31, 2026 and operating cash flow of $2.7 million.
Rigel highlighted progress in its R289 Phase 1b study and broader olutasidenib collaborations in hematologic cancers and high‑grade glioma. The company received notice in April 2026 that Eli Lilly will terminate their global RIPK1 collaboration effective June 15, 2026, after which Rigel expects to regain full rights to the compounds. In May 2026 Rigel refinanced its term loan into a new $40.0 million revolving credit facility with MidCap.
Rigel Pharmaceuticals reported strong Q3 2025 results. Total revenue was $69,462 (thousands), driven by net product sales of $64,067 (thousands) and collaboration revenue of $5,395 (thousands). Operating income reached $28,420 (thousands), and net income was $27,900 (thousands), or diluted EPS of $1.46. Gross product sales were $85,624 (thousands) offset by $21,557 (thousands) in discounts and allowances.
For the nine months ended September 30, 2025, revenue was $224,480 (thousands) and net income was $98,959 (thousands), aided by a $39,981 (thousands) release of cost share liability recognized in Q2. Cash, cash equivalents and short‑term investments were $137,200 (thousands) as of September 30, 2025. Customer concentration remained high, with McKesson accounting for 48% of Q3 net product sales. Shares outstanding were 18,151,344 as of October 30, 2025.